Spring Bank Pharmaceuticals Presents Positive Phase 1 Data on SB 9200 at the 2015 American Association for the Study of Liver Diseases Annual Meeting SB 9200 Mechanism of Action (MOA) Believed to Modulate Innate ImmunityData Support Further Evaluation of SB 9200 in Combination with Direct Acting Anti-Viral Agents in HCV-Infected Patients

MILFORD, Mass., Nov. 16, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced a poster presentation for its lead Small Molecule Nucleic Acid Hybrid (SMHN) antiviral compound, SB 9200, for the treatment of Hepatitis C (HCV) infection at the 2015 American Association for the Study of Liver Diseases (AASLD) Annual Meeting taking place November 13-17, 2015, in San Francisco. "The results presented at AASLD show that SB 9200 positively impacted viral load in otherwise healthy, non-cirrhotic Hepatitis C-infected patients via innate immune activation," said Kris Iyer,...